SCHEMBL4721628

SCHEMBL4721628

CCCCOc1ccn[c]c1-c1cccc2ccccc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1B P28222 7/20 0.47
HTR1D P28221 2/20 0.45
GAA P10253 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
CNR1 P21554 3/20 0.43
CNR2 P34972 3/20 0.43
TLR8 Q9NR97 1/20 0.42
CYP2C9 P11712 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP19A1 P11511 1/20 0.41
CYP2C19 P33261 1/20 0.41
PDE5A O76074 1/20 0.39
PDE4A P27815 1/20 0.39
PDE4B Q07343 1/20 0.39
PDE4C Q08493 1/20 0.39
PDE4D Q08499 1/20 0.39
MCHR1 Q99705 1/20 0.39
SLC6A4 P31645 1/20 0.39
HRH1 P35367 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4724637 0.94 HTR1B (0.43) HTR1BHTR1DTDP1CNR1CNR2
SCHEMBL4724855 0.88 ENPP1 (0.44) HTR1BHTR1DL3MBTL1TLR8PDE5A
SCHEMBL4723799 0.81 HTR1B (0.43) HTR1BHTR1DGAATDP1L3MBTL1
SCHEMBL4724144 0.81 ALDH1A1 (0.41) TDP1CNR2CYP1A2CYP2C19SLC6A4
SCHEMBL4719732 0.78 CYP2C9 (0.42) L3MBTL1TLR8CYP2C9CYP1A2CYP19A1
SCHEMBL4767284 0.76 HTR1B (0.46) HTR1BHTR1DGAATDP1L3MBTL1
SCHEMBL4722874 0.75 HTR1B (0.45) HTR1BHTR1DGAATDP1L3MBTL1
SCHEMBL4720726 0.74 TLR8 (0.39) HTR1BHTR1DGAATDP1L3MBTL1
SCHEMBL4723786 0.74 HTR1B (0.39) HTR1BHTR1DGAATDP1L3MBTL1
SCHEMBL4724147 0.74 HTR1B (0.39) HTR1BHTR1DGAATDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors PFIZER INC. 2008-07-24 US disclosed
EP-1874780-A1 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2008-01-09 EP disclosed
WO-2006100591-A1 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors TBXA2R, P2RY4, PF4 HTR1B 111/4885HTR1D 94/4885GAA 3876/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.